title: Encephalopathy associated with ifosphamide/mesna therapy.
authors.forename: C A
authors.initials: CA
authors.lastname: Meanwell
authors.forename: A E
authors.initials: AE
authors.lastname: Blake
authors.forename: T N
authors.initials: TN
authors.lastname: Latief
authors.forename: G
authors.initials: G
authors.lastname: Blackledge
authors.forename: J J
authors.initials: JJ
authors.lastname: Mould
authors.forename: D R
authors.initials: DR
authors.lastname: Blake
authors.forename: I C
authors.initials: IC
authors.lastname: Shaw
authors.forename: L
authors.initials: L
authors.lastname: Honigsberger
authors.forename: D
authors.initials: D
authors.lastname: Spooner
authors.forename: A C
authors.initials: AC
authors.lastname: Williams
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001927:Brain Diseases / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects*; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000188:drug therapy
chemical_list: D008623:Mercaptoethanol; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide